Novartis India Limited (NSE:NOVARTIND)
1,388.90
+24.60 (1.80%)
Jun 19, 2026, 3:29 PM IST
Novartis India Revenue
In the fiscal year ending March 31, 2026, Novartis India had annual revenue of 3.54B INR, down -0.54%. Novartis India had revenue of 905.50M in the quarter ending March 31, 2026, with 7.95% growth.
Revenue
3.54B
Revenue Growth
-0.54%
P/S Ratio
9.68
Revenue / Employee
63.27M
Employees
56
Market Cap
34.28B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 3.54B | -19.40M | -0.54% |
| Mar 31, 2025 | 3.56B | 212.00M | 6.33% |
| Mar 31, 2024 | 3.35B | -436.70M | -11.53% |
| Mar 31, 2023 | 3.79B | -211.30M | -5.28% |
| Mar 31, 2022 | 4.00B | 185.20M | 4.86% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Indoco Remedies | 18.45B |
| Aarti Pharmalabs | 18.19B |
| Innova Captab | 16.30B |
| Solara Active Pharma Sciences | 13.69B |
| Windlas Biotech | 9.04B |
| Orchid Pharma | 8.11B |
| RPG Life Sciences | 7.08B |
| Ind-Swift Laboratories | 6.41B |
Novartis India News
- 4 months ago - Pharma sector stocks today, Feb 20: Novartis India rally 20%, Biocon jumps 1.36%, Alembic rises 1.11% - Business Upturn
- 4 months ago - Novartis India shares in focus today as mandatory open offer triggered after 70.68% stake deal - Business Upturn
- 4 months ago - Novartis India shares surge 14.65% today after Novartis AG to sell 70.68% stake - Business Upturn
- 1 year ago - Novartis India stock surges 9% as Alkem Labs eyes ₹2,000 crore acquisition - Business Upturn